Analyst Price Targets — ELAN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 1:33 pm | Steve Dechert | KeyBanc | $29.00 | $27.13 | StreetInsider | 'Elanco Animal Health (ELAN) set up well for beats and raises'; PT Raised to $29 at KeyBanc |
| February 24, 2026 7:50 pm | Daniel Clark | Leerink Partners | $30.00 | $26.37 | TheFly | Elanco price target raised to $30 from $26 at Leerink |
| January 29, 2026 2:33 pm | — | UBS | $30.00 | $24.17 | TheFly | Elanco price target raised to $30 from $27 at UBS |
| January 22, 2026 8:42 am | David Westenberg | Piper Sandler | $30.00 | $24.30 | StreetInsider | Piper Sandler Upgrades Elanco Animal Health (ELAN) to Overweight |
| December 18, 2025 12:55 pm | — | Morgan Stanley | $22.00 | $22.08 | TheFly | Elanco price target raised to $22 from $18 at Morgan Stanley |
| December 8, 2025 9:26 pm | — | Barclays | $30.00 | $21.69 | TheFly | Elanco initiated with an Overweight at Barclays |
| November 20, 2025 9:21 pm | — | KeyBanc | $27.00 | $21.46 | TheFly | Elanco initiated with an Overweight at KeyBanc |
| November 19, 2025 1:20 pm | — | Argus Research | $25.00 | $21.46 | TheFly | Elanco upgraded to Buy from Hold at Argus |
| November 5, 2025 6:03 pm | — | Stifel Nicolaus | $27.00 | $21.91 | TheFly | Elanco price target raised to $27 from $23 at Stifel |
| October 20, 2025 1:38 pm | — | UBS | $25.00 | $21.64 | TheFly | Elanco price target raised to $25 from $19 at UBS |
Latest News for ELAN
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Douglas Lane and Associates LLC cut its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,048,092 shares of the company's stock after selling 396,176 shares during the quarter. Douglas Lane
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dog Adjustable collar fits comfortably and securely on a dog of any size Strengthens Elanco's 25-year Advantage brand family Available at pet specialty, dollar, grocery and mass retailers, with a suggested retail price below $25** INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Elanco Animal Health…
SG Americas Securities LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 25.3% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 95,525 shares of the company's stock after selling 32,403 shares during the period. SG Americas Securities LLC's
Elanco Animal Health Incorporated (NYSE: ELAN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.